Bifiform, 40 pcs.

Enterococcus faecium and Bifidobacterium longum strains included in the drug are natural symbiotic bacteria that inhabit the gastrointestinal tract. The drug has a normalizing effect on the quantitative and qualitative composition of the intestinal microflora.

The action is conditioned by direct direct effect of ingredients of the preparation (high antagonistic activity in respect of pathogenic and conditionally pathogenic microorganisms) and indirect – stimulation of local intestinal immunity (activation of immunoglobulin A synthesis, induction of endogenous interferon synthesis).

Bifidobacterium longum has high survival rate in human intestine and high growth rate. Inclusion of Enterococcus faecium apathogenic enterococcus that normally colonizes small intestine allows to have a positive effect on condition and digestive functions of not only large but also small intestine, especially in case of fermentative dyspepsia and flatulence phenomena.

Indications

Diarrhea caused by acute and exacerbation of chronic gastroenteritis, rotavirus infection; antibiotic-associated diarrhea; traveler’s diarrhea;
– in complex therapy of acute intestinal infections;
– in complex therapy of chronic diseases of the gastrointestinal tract, such as colitis, irritable bowel syndrome and other gastrointestinal disorders of functional origin;
– normalization of intestinal microflora, treatment and prevention of dysbiosis and maintenance of the immune system in children over 2 years of age and adults;
– lactose intolerance;
– as part of complex standard eradication therapy in patients with Helicobacter pylori infection.

Pharmacological effect

The Enterococcus faecium and Bifidobacterium longum strains included in the drug are natural symbiotic bacteria that inhabit the gastrointestinal tract. The drug has a normalizing effect on the quantitative and qualitative composition of the intestinal microflora.
The effect is due to both the immediate direct effect of the components included in the drug (high antagonistic activity against pathogenic and conditionally pathogenic microorganisms), and the indirect effect – stimulation of the local intestinal immune system (activation of the synthesis of immunoglobulin A, induction of the synthesis of endogenous interferon).
Bifidobacterium longum has a high survival rate in the human intestine and a high growth rate. The inclusion in the preparation of the apathogenic enterococcus Enterococcus faecium, which normally colonizes the small intestine, makes it possible to have a positive effect on the condition and digestive functions of not only the large intestine, but also the small intestine, especially in the presence of fermentative dyspepsia and flatulence.

Special instructions

Do not exceed the maximum daily dose.

Active ingredient

Bifidobacterium longum, Enterococcus fecium

Composition

1 enteric capsule contains:

Active ingredients:
Enterococcus faecium not less than 1 × 107 CFU
Bifidobacterium longum not less than 1 × 107 CFU

Excipients:
anhydrous dextrose 162.5 mg, yeast starter 17.5 mg, locust bean gum 12.5 mg, magnesium stearate 2.5 mg, lactulose 0.5 mg.

Composition of the capsule shell:
gelatin 48.0 mg, titanium dioxide (0.96 mg)*, magnesium stearate 0.5 mg, methacrylic acid and methyl methacrylate copolymer [1:1] 2.2 mg, methacrylic acid and ethyl acrylate copolymer [1:1] [30% dispersion] 7.7 mg, talc 5.6 mg, macrogol 6000 1.5 mg, soybean oil purified 0.8 mg, diacetylated glycerides 0.3 mg.
*weight of titanium dioxide is included in the total weight of the gelatin capsule.

Pregnancy

The use of Bifiform during pregnancy and lactation is considered safe, since the drug is not absorbed and does not have a systemic effect.

Contraindications

Individual hypersensitivity to the components of the drug.

Side Effects

When used in recommended doses according to established indications, no adverse reactions were identified.

Interaction

The drug can be used in combination with other medications. Concomitant use with antibiotics is permitted.

Overdose

Overdose symptoms have not been previously recorded. In case of significant excess of recommended doses, medical supervision is advisable.

Recommendations for use

For acute diarrhea, the drug should be taken 1 capsule 4 times a day until stool normalizes. Then the drug should be continued at a dose of 2-3 capsules per day until the symptoms disappear completely.
To normalize the intestinal microflora and support the immune system, the drug is prescribed in a dose of 2-3 capsules per day for 10-21 days.
Patients with lactose intolerance are recommended to take the drug 1 capsule 3 times a day.
When carrying out eradication therapy, Bifiform is prescribed 2 capsules 2 times a day for two weeks from the first day of eradication therapy.
Children from 2 years old: 1 capsule 2-3 times a day.
The duration of treatment can be adjusted according to the doctor’s recommendation.
When prescribing to children and patients who cannot swallow a whole capsule, it should be carefully broken, carefully, avoiding loss, pour the contents into a spoon and mix with a small amount of liquid.
If you have any questions, please consult your doctor.

Storage conditions

Store at a temperature not exceeding 25 °C.
Keep out of the reach of children.

Shelf life

2 years.
Do not use after the expiration date stated on the package.

Manufacturer

Pfizer Consumer Manufacturing Italy S.R.L., Italy